Q3 2024 Earnings Estimate for Bio-Path Holdings, Inc. (NASDAQ:BPTH) Issued By Roth Capital

Bio-Path Holdings, Inc. (NASDAQ:BPTH) – Equities researchers at Roth Capital lowered their Q3 2024 earnings per share (EPS) estimates for shares of Bio-Path in a research report issued on Thursday, August 15th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($1.02) per share for the quarter, down from their prior forecast of ($0.93). The consensus estimate for Bio-Path’s current full-year earnings is ($5.53) per share. Roth Capital also issued estimates for Bio-Path’s Q4 2024 earnings at ($1.01) EPS, FY2024 earnings at ($6.20) EPS, FY2025 earnings at ($4.04) EPS, FY2026 earnings at ($3.91) EPS, FY2027 earnings at ($3.78) EPS and FY2028 earnings at $4.27 EPS.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the business earned ($10.60) EPS.

Other equities research analysts also recently issued research reports about the company. Roth Mkm reissued a “buy” rating and issued a $20.00 price target on shares of Bio-Path in a report on Monday, July 8th. StockNews.com assumed coverage on Bio-Path in a report on Thursday, May 2nd. They set a “sell” rating for the company.

Bio-Path Price Performance

NASDAQ:BPTH opened at $1.48 on Monday. Bio-Path has a 52 week low of $1.31 and a 52 week high of $21.60. The firm has a 50 day moving average of $1.79 and a 200 day moving average of $3.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.